# LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma

> **NCT00062868** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 74 (actual)

## Conditions studied

- Hodgkin Disease
- Non Hodgkin Lymphoma
- Lymphoepithelioma
- Leiomyosarcoma

## Interventions

- **BIOLOGICAL:** LMP1/2 CTLs (ALCI - Group A)
- **BIOLOGICAL:** LMP1/2 CTLs (ALCI - Group B)
- **BIOLOGICAL:** LMP1/2 CTLs (ALCI - Group C)
- **BIOLOGICAL:** LMP2 CTLs (ALSCER - Group A)
- **BIOLOGICAL:** LMP2 CTLs (ALSCER - Group B)
- **BIOLOGICAL:** LMP2 CTLs (ALSCER - Group C)
- **BIOLOGICAL:** LMP1/2 CTLs (ALCI - Expansion - Group A)
- **BIOLOGICAL:** LMP1/2 CTLs (ALCI - Expansion Group B)
- **BIOLOGICAL:** LMP1/2 CTLs (ALCI - Expansion Group C)

## Key facts

- **NCT ID:** NCT00062868
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2014-04
- **Final completion:** 2020-04
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062868, "LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00062868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*